DGAP-News

​​​​​​​Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024

DGAP-News: Epigenomics AG / Key word(s): Bond/Miscellaneous ​​​​​​​Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024 20.04.2021 / 15:39 The issuer is solely responsible for the content of this announcement. Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024

Berlin (Germany) and San Diego (U.S.A.), April 20, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that convertible bonds with a nominal value of EUR 4,357,606.00 have been converted into 3,961,460 new shares (ISIN DE000A3H2184) in the first conversion period of the mandatory convertible bond 2021/2024. Accordingly, the number of issued shares increased from 5,891,230 to 9,852,690 no par value registered shares of the Company. The Company's share capital increases correspondingly by EUR 3,961,460.00 to EUR 9,852,690.00. The outstanding portion of the mandatory convertible bond 2021/2024 therefore has a nominal value of EUR 1,142,394.00.

The new shares, which carry full dividend rights as of January 1, 2021, were admitted to trading on the stock exchange on April 16, 2021. Delivery of the new shares to the custodian banks will be carried out promptly.

The first conversion period ran from April 1 to 14, 2021. The next opportunity to convert is offered to creditors of the convertible bond from July 1 to 14, 2021.
 

About Epigenomics
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.